Stock listing
OTC:LOBEF Lobe Sciences Ltd Stock
US listing (OTC) of Lobe Sciences Ltd · home listing CSE:LOBE
Follow Lobe Sciences Ltd into a list and get an email when it puts out news.
Share price · OTC:LOBEF
$0.036 USD -0.003 (-7.2%)
Close on Nov 20, 2026
- Day range
- $0.032 – $0.036 USDNov 20, 2026
- Volume
- 43,274 sharesNov 20, 2026
- Market cap
- $11.06M USDAt the close on Nov 20, 2026 · price × 308.2M shares outstanding
- 52-week range
- $0.0021 – $0.063 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3,324 USDMedian day 35,000 shares · 4 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| CSE:LOBE · Home | $0.05 CAD | 0.00 (0.0%) | 26,000 | $0.05 | $0.05 | $0.05 | $0.05 | Close on Nov 20, 2026 |
| OTC:LOBEF | $0.036 USD | -0.003 (-7.2%) | 43,274 | $0.033 | $0.036 | $0.032 | $0.039 | Close on Nov 20, 2026 |
| Frankfurt:LOBE | €0.025 EUR | -0.005 (-15.5%) | — | €0.025 | €0.025 | €0.025 | €0.029 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · OTC:LOBEF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.027 | -0.002 | -8.2% | $0.024 | $0.029 | $0.021 | 268,200 | |
| $0.029 | +0.002 | +8.2% | $0.029 | $0.029 | $0.029 | 15,000 | |
| $0.027 | -0.003 | -10.3% | $0.027 | $0.027 | $0.027 | 23,100 | |
| $0.030 | +0.003 | +10.3% | $0.029 | $0.030 | $0.025 | 303,700 | |
| $0.027 | -0.004 | -13.4% | $0.040 | $0.040 | $0.027 | 26,300 | |
| $0.031 | +0.002 | +8.7% | $0.029 | $0.031 | $0.029 | 12,000 | |
| $0.029 | -0.011 | -26.8% | $0.038 | $0.038 | $0.029 | 120,100 | |
| $0.040 | -0.001 | -2.5% | $0.040 | $0.040 | $0.040 | 22,900 | |
| $0.041 | +0.011 | +38.2% | $0.033 | $0.041 | $0.033 | 175,300 | |
| $0.029 | +0.002 | +6.5% | $0.028 | $0.029 | $0.026 | 229,800 | |
| $0.028 | +0.001 | +2.6% | $0.029 | $0.029 | $0.025 | 47,200 | |
| $0.027 | -0.009 | -26.2% | $0.030 | $0.031 | $0.026 | 417,900 | |
| $0.036 | +0.003 | +7.7% | $0.036 | $0.036 | $0.032 | 292,000 | |
| $0.034 | 0.000 | -0.9% | $0.036 | $0.036 | $0.034 | 35,000 | |
| $0.034 | +0.001 | +2.4% | $0.034 | $0.034 | $0.034 | 100 | |
| $0.033 | +0.000 | +0.3% | $0.037 | $0.037 | $0.033 | 1,500 | |
| $0.033 | 0.000 | -0.9% | $0.036 | $0.036 | $0.032 | 45,100 | |
| $0.033 | -0.011 | -24.4% | $0.035 | $0.039 | $0.033 | 85,400 | |
| $0.044 | 0.000 | 0.0% | $0.044 | $0.044 | $0.044 | 0 | |
| $0.044 | +0.009 | +23.8% | $0.040 | $0.044 | $0.040 | 3,700 | |
| $0.036 | -0.014 | -28.5% | $0.033 | $0.036 | $0.033 | 33,900 | |
| $0.050 | +0.013 | +34.9% | $0.037 | $0.050 | $0.032 | 238,700 | |
| $0.037 | 0.000 | -1.1% | $0.035 | $0.037 | $0.032 | 27,000 | |
| $0.037 | -0.004 | -9.2% | $0.035 | $0.039 | $0.035 | 318,230 | |
| $0.041 | +0.001 | +3.5% | $0.042 | $0.042 | $0.041 | 45,000 | |
| $0.040 | +0.001 | +3.4% | $0.038 | $0.040 | $0.037 | 3,500 | |
| $0.039 | -0.007 | -14.8% | $0.044 | $0.048 | $0.037 | 9,200 | |
| $0.045 | -0.008 | -15.4% | $0.053 | $0.053 | $0.039 | 39,400 | |
| $0.053 | 0.000 | -0.2% | $0.048 | $0.053 | $0.048 | 2,400 | |
| $0.054 | +0.004 | +7.2% | $0.050 | $0.054 | $0.047 | 226,600 | |
| $0.050 | 0.000 | 0.0% | $0.050 | $0.050 | $0.050 | 0 | |
| $0.050 | 0.000 | 0.0% | $0.044 | $0.050 | $0.044 | 10,500 | |
| $0.050 | +0.001 | +1.6% | $0.043 | $0.050 | $0.043 | 257,300 | |
| $0.049 | +0.002 | +5.4% | $0.048 | $0.050 | $0.048 | 141,500 | |
| $0.047 | -0.007 | -12.7% | $0.051 | $0.051 | $0.043 | 108,200 | |
| $0.053 | +0.002 | +4.7% | $0.054 | $0.054 | $0.053 | 4,800 | |
| $0.051 | -0.003 | -6.3% | $0.052 | $0.054 | $0.051 | 107,900 | |
| $0.054 | -0.001 | -1.1% | $0.052 | $0.055 | $0.052 | 46,500 | |
| $0.055 | +0.002 | +3.2% | $0.058 | $0.059 | $0.052 | 132,500 | |
| $0.053 | -0.005 | -8.6% | $0.056 | $0.056 | $0.052 | 16,600 | |
| $0.058 | +0.001 | +1.9% | $0.050 | $0.059 | $0.050 | 49,800 | |
| $0.057 | +0.001 | +1.1% | $0.057 | $0.060 | $0.052 | 23,200 | |
| $0.057 | -0.003 | -5.7% | $0.052 | $0.061 | $0.052 | 59,800 | |
| $0.060 | +0.000 | +0.3% | $0.058 | $0.060 | $0.052 | 4,066 | |
| $0.060 | +0.002 | +3.1% | $0.056 | $0.060 | $0.051 | 104,000 | |
| $0.058 | -0.004 | -6.0% | $0.055 | $0.063 | $0.055 | 10,400 | |
| $0.062 | 0.000 | 0.0% | $0.062 | $0.062 | $0.062 | 0 | |
| $0.062 | +0.002 | +2.8% | $0.057 | $0.062 | $0.055 | 24,300 | |
| $0.060 | -0.002 | -2.6% | $0.062 | $0.062 | $0.058 | 10,300 | |
| $0.062 | +0.002 | +2.7% | $0.062 | $0.062 | $0.051 | 40,500 | |
| $0.060 | 0.000 | 0.0% | $0.060 | $0.060 | $0.060 | 0 | |
| $0.060 | +0.002 | +3.1% | $0.060 | $0.062 | $0.057 | 13,700 | |
| $0.058 | -0.005 | -7.5% | $0.050 | $0.058 | $0.050 | 142,700 | |
| $0.063 | +0.007 | +12.5% | $0.056 | $0.063 | $0.056 | 9,600 | |
| $0.056 | +0.050 | +935.2% | $0.050 | $0.058 | $0.050 | 73,200 |
Splits
1 split · OTC:LOBEF · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-6 | Consolidation |
- Ticker
- OTC:LOBEF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Oct 20, 2026
Lobe Sciences Appoints Tracy L. Goeken, M.D., as Chief Medical Officer
Latest deck · Sep 15, 2026
Investor Presentation (September 2026)
Investor deck · 29 slides
Latest news
Lobe Sciences Appoints Tracy L. Goeken, M.D., as Chief Medical Officer
Oct 20, 2026
Closed $0.034 (-0.9%) on Oct 20, 2026
Lobe Sciences Appoints Annette Grimaldi, Former Head of Life Sciences Investment Banking at BMO Capital Markets, to Board of Directors
Oct 14, 2026
Closed $0.033 (-24.4%) on Oct 14, 2026
Lobe Sciences Announces Proposed Capital Markets Initiatives to Support Planned Growth
Oct 8, 2026
Closed $0.05 (+34.9%) on Oct 8, 2026
Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Sep 14, 2026
Closed $0.053 (-8.6%) on Sep 14, 2026
Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement
Aug 31, 2026
Closed $0.062 (+2.8%) on Sep 1, 2026
Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement
Aug 28, 2026
Closed $0.06 (-2.6%) on Aug 31, 2026
Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement
Aug 20, 2026
Closed $0.056 (+935.2%) on Aug 20, 2026
Lobe Sciences Reports Third Quarter 2026 Financial Results
Aug 18, 2026
Closed $0.0058 (+5.5%) on Aug 18, 2026
Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders
Aug 5, 2026
Closed $0.0060 (+9.1%) on Aug 5, 2026
Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares
Jun 9, 2026
Closed $0.0080 (0.0%) on Jun 10, 2026
Lobe Sciences Ltd on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 21 in the last 12 months · 61 in all · newest Oct 20, 2026 · oldest 2023
- Decks
- 6 decks · latest Sep 15, 2026
Where Lobe Sciences Ltd is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| CSE:LOBE · Home listing | CSE | Canada | CAD |
| OTC:LOBEF · This page | OTC | United States | USD |
| Cboe Canada:LOBE | Cboe Canada | Canada | CAD |
| Frankfurt:LOBE | Frankfurt | Germany | EUR |
Valuation
Price/book 9.5× against a median of 1.8×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to May 31, 2026 · price Nov 20, 2026
- Enterprise value
- $12.74M CAD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 9.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P/TSX Composite
- 0.31
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Lobe Sciences Ltd · CSE:LOBE | US$12.52M | US$8.89M | n/a | n/a | n/a | 9.5× | n/a | 0.0× | 0.31 |
| Devonian Health Group, Inc. · TSXV:GSD | US$13.09M | US$12.59M | n/a | 6.0× | n/a | 2.7× | −204.1% | 0.0× | 0.12 |
| Bolt Biotherapeutics, Inc. · NASDAQ:BOLT | US$12.80M | US$18.89M | n/a | 7.5× | n/a | 1.5× | n/a | 2.4× | 0.52 |
| Avai Bio, Inc. · OTC:AVAI | US$12.79M | US$12.67M | n/a | n/a | n/a | n/a | n/a | n/a | 0.28 |
| Neuphoria Therapeutics Inc. · NASDAQ:NEUP | US$12.72M | −US$6.03M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 0.61 |
| Seres Therapeutics, Inc. · NASDAQ:MCRB | US$12.64M | US$30.89M | n/a | 14.5× | n/a | 0.6× | n/a | 1.7× | 1.21 |
| Passage Bio, Inc. · NASDAQ:PASG | US$12.61M | −US$7.55M | n/a | n/a | n/a | 252× | n/a | 0.0× | 1.94 |
| Allarity Therapeutics, Inc. · NASDAQ:ALLR | US$12.56M | US$21.48M | n/a | 61.4× | n/a | n/a | n/a | n/a | 1.40 |
| Biophytis SA · EURONEXT:ALBPS | US$12.47M | US$19.44M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| MIRA Pharmaceuticals, Inc. · NASDAQ:MIRA | US$12.23M | US$5.26M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 1.48 |
| Genflow Biosciences PLC · LSE:GENF | US$12.06M | US$11.23M | n/a | n/a | n/a | 48.5× | n/a | 0.0× | n/a |
| Median of the others | US$12.63M | US$12.63M | 11.0× | 1.8× | −204.1% | 0.0× | 0.91 |
Team and board
Officers
| Officer | Role |
|---|---|
| Frederick D. Sancilio | Chairman & Chief Executive Officer |
| Bob Miller | Senior Vice President, Quality and Operations |
| Mirza Rahimani | Vice President of Finance |
| Maghsoud Dariani | Chief Science Officer |
| Tracy L. Goeken | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Frederick D. Sancilio | Chairman & Chief Executive Officer |
| Annette Grimaldi | Director |
| Harry R. Jacobson | Director |
| Marco Lucio Mastrodonato | Director |
| Nick Karakochuk | Director |
| Wesley Ramjeet | Director |
Events
- Next results
- Dec 28, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Apr 28, 2023 · Before open | −14.3% |
| Q1 2023 | Dec 22, 2022 · After close | 0.0% |
| Q3 2022 | Jul 20, 2022 · Before open | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 29 slides | Sep 15, 2026 |
| Investor Presentation (September 2026) | Investor deck | 21 slides | Sep 15, 2026 |
| Conference Presentation (September 2026) | Conference | 22 slides | Sep 15, 2026 |
| Investor Presentation (July 2026) | Investor deck | 21 slides | July 2026 |
| Investor Presentation (June 2026) | Investor deck | 23 slides | June 2026 |
| Investor Presentation (April 2026) | Investor deck | 21 slides | April 2026 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of common shares Closed: C$2.16M raised · C$0.085 a share Use of proceeds: Working capital, general corporate purposes, and advancing the S-100 drug candidate for sickle cell disease, partly via subsidiary Applied Lipid Technologies | Aug 31, 2026 | |
| Private placement of common shares Closed: C$950,000 raised · C$0.065 a share Use of proceeds: Working capital, general corporate purposes and advancing the S-100 drug candidate for sickle cell disease toward human clinical trials | Apr 20, 2026 | US$695,461 |
| Private placement of common shares Closed: C$341,425 raised · C$0.04 a share Use of proceeds: General corporate purposes, including working capital and ongoing operational needs | Aug 15, 2025 | US$247,302 |
| Private placement of series A-1 Preferred Stock of subsidiary Cynaptec Pharmaceuticals, Inc. Closed: US$6M raised · US$1.66 a share Use of proceeds: Fund preclinical research (including IND enabling studies), Phase 1 and Phase 2a clinical studies for Conjugated Psilocin | Apr 15, 2025 | |
| Convertible notes Terms changed: C$678,450 | Apr 5, 2025 | US$477,244 |
| Convertible note Closed: US$250,000 raised | Apr 5, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CAD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 136.2K | 840.5K | 0 | 0 | 884.8K | 773.8K | 0 | 0 | |
| Cost of revenue | 0 | 1.76K | 24.0K | 0 | ||||||
| Gross profit | 0 | 134.4K | 816.5K | 0 | ||||||
| Research and development | 641.1K | 386.2K | 1.25M | 418.3K | 1.37M | 0 | ||||
| Selling, general and administrative | 3.54M | 1.78M | 2.88M | 3.69M | 4.94M | 2.73M | 3.27M | 148.4K | 51.9K | 45.8K |
| Operating income | -4.18M | -2.12M | -3.36M | -4.12M | -6.32M | -2.41M | -2.87M | -148.4K | -51.9K | -45.8K |
| Depreciation and amortization | 0 | 84.7K | 43.7K | 10.2K | 10.2K | 10.2K | 371.0K | 246.2K | ||
| EBITDA | -4.18M | -2.03M | -3.32M | -4.11M | -6.31M | -2.40M | -2.50M | 97.8K | ||
| Interest expense | 596.6K | 186.6K | 38.6K | 0 | 0 | 43.0K | 0 | 102 | 0 | 0 |
| Income before tax | -4.86M | -4.39M | -4.50M | -12.3M | -23.8M | -3.44M | -754.4K | -148.3K | -51.8K | -56.0K |
| Income tax | -1.02M | |||||||||
| Net income | -4.43M | -4.42M | -4.71M | -12.3M | -9.66M | -3.44M | -754.4K | -148.3K | -51.8K | -56.0K |
| Earnings per share, basic | -0.02 | -0.03 | -0.06 | -0.32 | -0.04 | -0.02 | -0.01 | -0.03 | -0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.85M | 237.8K | 140.3K | 907.5K | 1.14M | 172.1K | 512.8K | 2.66K | 29.5K | 34.5K |
| Short-term investments | 1.69M | 0 | 6.28M | 0 | ||||||
| Receivables | 47.5K | 9.34K | 14.9K | 18.3K | 1.76M | 615.4K | 1.10M | 71.8K | ||
| Inventory | 0 | 17.0K | 0 | |||||||
| Current assets | 7.59M | 258.6K | 319.4K | 1.04M | 9.67M | 1.17M | 1.99M | 2.56M | 30.3K | 34.9K |
| Property, plant and equipment | 571.4K | |||||||||
| Total assets | 7.59M | 258.6K | 2.30M | 1.75M | 12.1M | 13.0M | 6.72M | 7.44K | 30.3K | 34.9K |
| Accounts payable | 1.98M | 784.3K | 1.92M | 1.20M | 745.4K | 376.8K | 331.1K | 115.4K | 616 | 396 |
| Current liabilities | 2.43M | 2.27M | 2.46M | 1.30M | 804.7K | 776.9K | 527.6K | 115.4K | 6.62K | 6.40K |
| Long-term debt | 273.3K | 1.11M | ||||||||
| Total liabilities | 2.70M | 3.37M | 2.46M | 1.30M | 804.7K | 897.1K | 527.6K | 132.1K | 6.62K | 6.40K |
| Shareholders' equity | 2.36M | -3.11M | -160.1K | 445.7K | 11.3M | 12.1M | 6.19M | -124.6K | 23.6K | 28.5K |
| Shares outstanding | 264.1M | 171.6M | 79.1M | 38.5M | 224.6M | 143.1M | 67.8M | 4.45M | 4.45M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.42M | -462.3K | -1.72M | -2.73M | -5.04M | -1.22M | -2.04M | -2.01M | -51.9K | -44.8K |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | -265.1K | 0 | 0 | 0 |
| Free cash flow | -1.42M | -462.3K | -1.72M | -2.73M | -5.04M | -1.22M | -2.31M | -26.9K | -51.9K | -44.8K |
| Cash from investing | 1.07M | 198.7K | -463.8K | -10.9M | ||||||
| Cash from financing | 8.76M | 563.5K | 950.0K | 2.50M | 4.92M | 718.7K | 474.7K | 18.9M | 46.9K | |
| Change in cash | 5.62M | 101.2K | -768.6K | -234.3K | 969.7K | -340.7K | -1.97M | 5.97M | -5.00K | -44.8K |
Cap table
Built by 6ix from Lobe Sciences Ltd’s releases · as of Oct 14, 2026
- Common shares
- 359,005,684
- Fully diluted
- 363,005,684
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 359,005,684 | Aug 31, 2026 |
| Options and RSUs | 4,000,000 | Oct 14, 2026 |
Warrants and options
| Lot |
|---|
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Aug 31, 2026 | 359,005,684 |
| Aug 31, 2026 | 333,593,922 |
| Aug 20, 2026 | 332,888,040 |
| May 31, 2026 | 308,182,160 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Annette Grimaldi | Director · Since at least Oct 14, 2026 |
| Bob Miller | Senior Vice President, Quality and Operations · Since at least Nov 4, 2026 |
| David Kideckel | Until Mar 9, 2026 · Past |
| Frederick D. Sancilio | Chairman & Chief Executive Officer · Since at least Oct 20, 2026 |
| Harry R. Jacobson | Director · Since at least Jun 9, 2026 |
| Maghsoud Dariani | Chief Science Officer · Since at least Nov 5, 2026 |
| Marco Mastrodonato | Director · Since at least Sep 9, 2025 |
| Mirza Rahimani | Vice President of Finance · Since at least Mar 9, 2026 |
| Nick Karakochuk | Director · Since at least Jan 13, 2026 |
| Tracy L. Goeken | Chief Medical Officer · Since Oct 20, 2026 |
All 12 people
| Person | Seat |
|---|---|
| Wesley Ramjeet | Director · Since at least Jun 9, 2026 |
| Yong Yao | Chief Financial Officer · Jun 3, 2025 – Nov 4, 2026 · Past |
Log in to ask 6ix AI your own questions about Lobe Sciences Ltd.